JP2015523553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523553A5 JP2015523553A5 JP2015512185A JP2015512185A JP2015523553A5 JP 2015523553 A5 JP2015523553 A5 JP 2015523553A5 JP 2015512185 A JP2015512185 A JP 2015512185A JP 2015512185 A JP2015512185 A JP 2015512185A JP 2015523553 A5 JP2015523553 A5 JP 2015523553A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- benzoflavone
- concentration
- weight
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 33
- OUGIDAPQYNCXRA-UHFFFAOYSA-N beta-naphthoflavone Chemical compound O1C2=CC=C3C=CC=CC3=C2C(=O)C=C1C1=CC=CC=C1 OUGIDAPQYNCXRA-UHFFFAOYSA-N 0.000 claims description 18
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 11
- 230000000699 topical effect Effects 0.000 claims description 10
- 206010039792 Seborrhoea Diseases 0.000 claims description 7
- 208000017520 skin disease Diseases 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 241001303601 Rosacea Species 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000004700 rosacea Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 6
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 239000000556 agonist Substances 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 101150055214 cyp1a1 gene Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168121.7 | 2012-05-15 | ||
| EP12168121.7A EP2664919A1 (fr) | 2012-05-15 | 2012-05-15 | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
| PCT/IB2013/053979 WO2013171696A1 (en) | 2012-05-15 | 2013-05-15 | Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523553A JP2015523553A (ja) | 2015-08-13 |
| JP2015523553A5 true JP2015523553A5 (enExample) | 2016-07-07 |
| JP6254580B2 JP6254580B2 (ja) | 2017-12-27 |
Family
ID=46801377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512185A Expired - Fee Related JP6254580B2 (ja) | 2012-05-15 | 2013-05-15 | 治療用皮脂抑制活性を有するＡｈＲ受容体のリガンドを同定する方法、および前記リガンド |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9480674B2 (enExample) |
| EP (2) | EP2664919A1 (enExample) |
| JP (1) | JP6254580B2 (enExample) |
| KR (1) | KR20150022827A (enExample) |
| CN (1) | CN104471391B (enExample) |
| AU (1) | AU2013261093A1 (enExample) |
| BR (1) | BR112014028307A2 (enExample) |
| CA (1) | CA2873191A1 (enExample) |
| CO (1) | CO7240392A2 (enExample) |
| HK (1) | HK1205252A1 (enExample) |
| IL (1) | IL235449A (enExample) |
| IN (1) | IN2014DN10283A (enExample) |
| MX (1) | MX2014013925A (enExample) |
| NZ (1) | NZ702357A (enExample) |
| PH (1) | PH12014502548A1 (enExample) |
| RU (1) | RU2014150505A (enExample) |
| SG (1) | SG11201407405VA (enExample) |
| WO (1) | WO2013171696A1 (enExample) |
| ZA (1) | ZA201408826B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2082736A1 (fr) | 2008-01-23 | 2009-07-29 | Jean Hilaire Saurat | Composition pharmaceutique à usage topique |
| EP3692999A1 (en) * | 2012-03-17 | 2020-08-12 | The Regents of the University of California | Fast diagnosis and personalized treatments for acne |
| EP2664919A1 (fr) | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
| WO2016022703A1 (en) * | 2014-08-06 | 2016-02-11 | Thesan Pharmaceuticals, Inc. | Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists |
| JP2016150916A (ja) * | 2015-02-17 | 2016-08-22 | 株式会社マンダム | 皮脂分泌抑制剤 |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| CN109715179A (zh) | 2016-04-21 | 2019-05-03 | 内科德生物群系公司 | 用于治疗皮肤病症的组合物和方法 |
| US11596657B2 (en) | 2016-10-04 | 2023-03-07 | Institut National De La Recherche Agronomique | Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders |
| EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3875098A1 (en) | 2020-03-04 | 2021-09-08 | Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases |
| WO2023064489A1 (en) * | 2021-10-14 | 2023-04-20 | Galileo Biosystems, Inc. | Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07501540A (ja) * | 1991-11-25 | 1995-02-16 | リチャードソン、ビックス、インコーポレーテッド | 皮膚シワ及び／又は皮膚萎縮を調節するための組成物 |
| BR9908870A (pt) * | 1998-03-16 | 2000-11-21 | Procter & Gamble | Processos para regularizarem a aparência da pele |
| CA2408152A1 (en) * | 2000-05-05 | 2001-11-15 | Wisconsin Alumni Research Foundation | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| US6902881B2 (en) * | 2000-10-13 | 2005-06-07 | President And Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
| US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
| EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
| FR2849597B1 (fr) * | 2003-01-08 | 2006-12-08 | Oreal | Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives |
| CA2593140C (en) * | 2005-01-05 | 2013-08-13 | Oliver Yoa-Pu Hu | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b) |
| US20060210515A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
| US20060210524A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin care composition |
| DE102005056890A1 (de) | 2005-11-28 | 2007-05-31 | Institut für Umweltmedizinische Forschung gGmbH | Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut |
| KR100798252B1 (ko) * | 2006-01-18 | 2008-01-24 | 주식회사 엘지생활건강 | ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물 |
| DE102006011747A1 (de) * | 2006-03-13 | 2007-09-27 | Symrise Gmbh & Co. Kg | Dermatologische und/oder kosmetische Zubereitungen |
| EP1842541A1 (en) * | 2006-03-29 | 2007-10-10 | G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg | Plant components and extracts and uses thereof |
| US20090208432A1 (en) | 2006-05-03 | 2009-08-20 | Symrise Gmbh & Co., Kg | AH Receptor Antagonists |
| US20080317684A1 (en) * | 2006-09-06 | 2008-12-25 | Isw Group, Inc. | Topical Compositions |
| EP2082736A1 (fr) | 2008-01-23 | 2009-07-29 | Jean Hilaire Saurat | Composition pharmaceutique à usage topique |
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| KR20110139397A (ko) * | 2010-06-23 | 2011-12-29 | 건국대학교 산학협력단 | 다약제 내성 저해 활성을 갖는 5,6-벤조플라본 화합물, 그의 제조 방법 및 이를 유효성분으로 포함하는 다약제 내성 저해용 조성물 |
| CN101953838A (zh) * | 2010-08-13 | 2011-01-26 | 李岱 | 吴茱萸次碱用于治疗银屑病的应用 |
| EP2664919A1 (fr) | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
-
2012
- 2012-05-15 EP EP12168121.7A patent/EP2664919A1/fr not_active Withdrawn
-
2013
- 2013-05-15 AU AU2013261093A patent/AU2013261093A1/en not_active Abandoned
- 2013-05-15 RU RU2014150505A patent/RU2014150505A/ru not_active Application Discontinuation
- 2013-05-15 CA CA2873191A patent/CA2873191A1/en not_active Abandoned
- 2013-05-15 KR KR20147035211A patent/KR20150022827A/ko not_active Withdrawn
- 2013-05-15 WO PCT/IB2013/053979 patent/WO2013171696A1/en not_active Ceased
- 2013-05-15 HK HK15105467.6A patent/HK1205252A1/xx unknown
- 2013-05-15 JP JP2015512185A patent/JP6254580B2/ja not_active Expired - Fee Related
- 2013-05-15 CN CN201380025088.6A patent/CN104471391B/zh not_active Expired - Fee Related
- 2013-05-15 EP EP13734844.7A patent/EP2850429A1/en not_active Withdrawn
- 2013-05-15 MX MX2014013925A patent/MX2014013925A/es unknown
- 2013-05-15 BR BR112014028307A patent/BR112014028307A2/pt not_active IP Right Cessation
- 2013-05-15 NZ NZ702357A patent/NZ702357A/en not_active IP Right Cessation
- 2013-05-15 SG SG11201407405VA patent/SG11201407405VA/en unknown
- 2013-05-15 IN IN10283DEN2014 patent/IN2014DN10283A/en unknown
-
2014
- 2014-11-02 IL IL235449A patent/IL235449A/en not_active IP Right Cessation
- 2014-11-07 US US14/536,507 patent/US9480674B2/en not_active Expired - Fee Related
- 2014-11-14 PH PH12014502548A patent/PH12014502548A1/en unknown
- 2014-12-02 ZA ZA2014/08826A patent/ZA201408826B/en unknown
- 2014-12-12 CO CO14273924A patent/CO7240392A2/es unknown
-
2016
- 2016-10-26 US US15/334,987 patent/US20170042856A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523553A5 (enExample) | ||
| Zhang et al. | Glioblastoma therapy using codelivery of cisplatin and glutathione peroxidase targeting siRNA from iron oxide nanoparticles | |
| Bagno et al. | Mechanism of action of mesenchymal stem cells (MSCs): impact of delivery method | |
| Gao et al. | Encapsulation of platinum prodrugs into PC7A polymeric nanoparticles combined with immune checkpoint inhibitors for therapeutically enhanced multimodal chemotherapy and immunotherapy by activation of the STING pathway | |
| Yu et al. | Macrophage‐associated osteoactivin/GPNMB mediates mesenchymal stem cell survival, proliferation, and migration via a CD44‐dependent mechanism | |
| US20210077625A1 (en) | Ray tracing technique for wireless channel measurements | |
| US10813919B2 (en) | Use of histone deacetylase inhibitors for enhancing immunotherapies | |
| JP6254580B2 (ja) | 治療用皮脂抑制活性を有するＡｈＲ受容体のリガンドを同定する方法、および前記リガンド | |
| CN111479575A (zh) | 包含化疗剂和检查点抑制剂的组合物及使用方法 | |
| JP2016500698A5 (enExample) | ||
| McCarthy et al. | In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer | |
| WO2014082085A1 (en) | Use of itk inhibitors for the treatment of cancer | |
| JP2015500820A (ja) | Ｅｇｆｒ阻害の有害反応を予防または処置するための組成物 | |
| JP2013203703A (ja) | Ｈｄｃ活性化阻害剤、ｈｄｃ活性化阻害剤組成物、鎮痒剤及び鎮痒剤組成物 | |
| WO2020160342A1 (en) | Methods and compositions for developing target specific exosome and growth factor products | |
| Li et al. | A Nanocapsule System Combats Aging by Inhibiting Age-Related Angiogenesis Deficiency and Glucolipid Metabolism Disorders | |
| WO2020023389A1 (en) | Reduced exposure compositions modulating therapeutic targets | |
| US12233087B2 (en) | Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions | |
| Wang et al. | Gamma-aminobutyric acid enhances miR-21-5p loading into adipose-derived stem cell extracellular vesicles to alleviate myocardial ischemia-reperfusion injury via TXNIP regulation | |
| Hayashi et al. | A prostacyclin agonist with thromboxane inhibitory activity for airway allergic inflammation in mice | |
| Ye et al. | The anti-inflammatory effect of the SOCC blocker SK&F 96365 on mouse lymphocytes after stimulation by Con A or PMA/ionomycin | |
| JP2017088559A (ja) | フィラグリン産生促進剤 | |
| Deng et al. | Extracellular matrix-mimetic hydrogel encapsulating myoblast exosomes attenuates muscle atrophy by targeting Nrf2-mitochondrial axis | |
| JP2010159252A (ja) | メラノソーム輸送抑制剤及びその方法 | |
| CN112955162A (zh) | 脂肪细胞介导的抗癌治疗剂的递送 |